Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
- DOI
- 10.1016/j.jtocrr.2023.100572
- Published
- 2023-09-09
- Container
- JTO Clin Res Rep
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2023.100572,
title = {Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.},
author = {Kim HR and Awad MM and Navarro A and Gottfried M and Peters S and Csőszi T and Cheema PK and Rodriguez-Abreu D and Wollner M and Yang JC and Mazieres J and Orlandi FJ and Luft A and Gümüş M and Kato T and Kalemkerian GP and Luo Y and Santorelli ML and Pietanza MC and Rudin CM.},
year = {2023},
journal = {JTO Clin Res Rep},
doi = {10.1016/j.jtocrr.2023.100572},
url = {https://doi.org/10.1016/j.jtocrr.2023.100572}
}RIS
TY - JOUR TI - Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC. AU - Kim HR AU - Awad MM AU - Navarro A AU - Gottfried M AU - Peters S AU - Csőszi T AU - Cheema PK AU - Rodriguez-Abreu D AU - Wollner M AU - Yang JC AU - Mazieres J AU - Orlandi FJ AU - Luft A AU - Gümüş M AU - Kato T AU - Kalemkerian GP AU - Luo Y AU - Santorelli ML AU - Pietanza MC AU - Rudin CM. PY - 2023 JO - JTO Clin Res Rep DO - 10.1016/j.jtocrr.2023.100572 UR - https://doi.org/10.1016/j.jtocrr.2023.100572 ER -
APA
HR, K., MM, A., A, N., M, G., S, P., T, C., PK, C., D, R., M, W., JC, Y., J, M., FJ, O., A, L., M, G., T, K., GP, K., Y, L., ML, S., MC, P., & CM., R. (2023). Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.. JTO Clin Res Rep. https://doi.org/10.1016/j.jtocrr.2023.100572
Source records
- europe-pmc · retrieved 2026-09-26T07:38:36.418Z
- doaj · retrieved 2026-09-26T07:38:36.394Z